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Hemorrhagic Fever Viruses
Jeffery A. Goad, PharmD; John Nguyen, MD
Viral hemorrhagic fever (VHF) viruses are diverse and include arenaviruses, bunyaviruses,
filoviruses, and flaviviruses. Lassa fever, South American hemorrhagic fever (HF), Rift Valley HF,
Crimean-Congo HF, Ebola, Marburg, yellow fever, and dengue fever are well known examples of
the hemorrhagic fever viruses. They are often difficult to diagnose and treat resulting in significant
morbidity and mortality. Transmission varies from vector borne to person-to-person. The common
clinical presentation includes fever, myalgia, microvascular damage, and hemorrahage as well as
a history of travel to the tropics. If VHF is suspected, strict infection control procedures must be
implemented to prevent the spread of these agents within the emergency department. Manage-
ment of VHF is largely supportive, but ribavirin has been useful for certain viruses. Key words:
arenavirus, bioterroism, bunyavirus, filovirus, flavivirus, hemorrhagic fever, ribavirin
‘‘COMMON things occur commonly.Uncommon things don’t. Therefore,
when you hear hoofbeats, think horses, not
zebras. What if the hoofbeats, this time, aren’t
horses?”1 The risk of exposure to a variety
of tropical viral diseases has increased due
to continued extension of human inhabitants
into tropical rain forests and shifting ecologi-
cal environments around equatorialregions of
the world. The potential to spread viral ill-
nesses worldwide has become a reality with
the expansion of international trade in combi-
nation with improved access to remote areas
with global transportation. Physicians in en-
demic regions need to be alert to the poten-
tial threat of viral hemorrhagic fevers (VHF).
In addition, physicians in nonendemic areas
need to be able to identify hemorrhagic viral
illness in international travelers from tropical
regions.
The key for physiciansin nonendemic areas
toidentify a VHF is to know the travel history
of the patient, incubation period, and com-
mon clinical signs and symptoms of hemor-
rhagic disease.2 Although hemorrhagic fever
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clinical presentation varies by virus, some
common features include fever, myalgias, and
petchiae, which may progress to prostration,
microvascular damage, and shock.3 Involve-
ment of the vascular system can manifest as
hypotension (vascular dysregulation), organ
dysfunction (vascular damage), and hemor-
rhage, which occurs mainly in patients with
thrombocytopenia or platelet dysfunction.2
When there is no significant travel history,
but clinical features of VHF are present, the
clinician might also consider bioterrorism.3,4
It is key that physicians be conscious of the
potential risk of tropical viral hemorrhagic
fevers for a number of reasons: (1) to ensure
proper diagnosis and rapid management of in-
dex cases; (2) to provide counseling and pos-
sible prophylaxis to close contacts; and (3)
to minimize the chances of nosocomial trans-
mission among health care staff caring for
such patients. All cases of VHF should be re-
ported to state and local health departments
as well as the Centers for Disease Control and
Prevention.
Viral hemorrhagic fever syndrome refers to
a clinical illness caused by a virus belong-
ing to 1 of 4 distinct families: Arenaviridae
(eg Lassa and South American HF), Bunyaviri-
dae (eg Rift Valley fever and Crimean-Congo
HF), Filoviridae (eg Ebola and Marburg), and
Flaviviridae (eg yellow fever and dengue).
They are all RNA viruses transmitted to
humans via contact with infected animal
66
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reservoirs or arthropod vectors. Human cases
of HF caused by these viruses are geographi-
cally restricted to the areas where their host
species live or were transported.5
Few treatments are available for VHFs. Al-
though there are no FDA approved drugs
for the treatment of VHF, ribavirin, a syn-
thetic guanosine analog with antiviral activ-
ity against DNA and RNA viruses, has been
used clinically against Bunyaviridae and Are-
naviridae. Ribavirin is available in both oral
and intravenous (IV) dosage forms as well as
an oral form in combination with injectable
interferon alpha-2b. Ribavirin has poor Cen-
tral Nervous System penetration, making it rel-
atively ineffective against neurologic effects
of VHF viruses. A major adverse effect of rib-
avirin is dose-related, reversible, hemolytic
anemia. Intramuscular injections, aspirin,
nonsteroidal anti-inflammatory agents, and
anticoagulant therapies are generally con-
traindicated for VHF and steroids are not
effective.4
The following is an overview of VHF, clin-
ical features, and medical management avail-
able to clinicians.
ARENAVIRUS
Overview
The arenaviruses havebeen separated on
the basis of immunologic and geographic
features into New and Old World sets.
At least 19 individual viruses have been
recognized. Four members of the New
World family, Junin (Argentine HF), Machupo
(Bolivian HF), Guanarito (Venezuelan HF),
and Sabia (Brazilian HF) cause human HF
(also referred to collectively as South Amer-
ican hemorrhagic fevers), while Lassa is an
Old World virus that causes HF in West Africa
(Sierra Leone, Guinea, Liberia, and Nigeria).6
All of the arenaviruses causing HF have a
specific rodent host with humans being the
accidental host. Patients will usually give a
history of travel within the last 21 days
(maximum incubation period) to West Africa
or South America in areas where the rodent
host is known to inhabit and contact with
rodent urine and feces, either by aerosoliza-
tion, ingestion, or direct contact.6 Nosoco-
mial person-to-person transmission occurs
with Lassa fever, but person-to-person spread
of South American HF is unlikely.3 The case-
fatality rate ranges from 2% to 15% in Lassa
fever and 15% to 30% in the South American
HFs.2
Clinical manifestations
Untreated, arenaviral infections are poten-
tially fatal diseases with focal hemorrhagic
manifestations and hypovolemic shock. Fever
is typically insidious in onset and is accom-
panied by headache and significant myalgia
and malaise. Relative bradycardia is common,
as is dysesthesia, particularly hyperesthesia of
the skin. Lassa fever, however, usually has less
neurologic involvement, thrombocytopenia,
leukopenia, and bleeding.6 However, when
bleeding is present, there is a high viremia or
an elevated aspartate aminotransferase; a poor
prognosis is more likely.7 Most infected indi-
viduals defervesce by 10 days, but a small per-
centage progress rapidly to shock, delirium,
respiratory distress, coma, and death.6
Infection with South American hemor-
rhagic viruses typically results in symp-
tomatic illness, the clinical features of which
are remarkably similar to those to Lassa fever
3 to 4 days after the onset of fever, malaise,
and myalgia. Patients manifest severe pros-
tration, headache, dizziness, back pain, and
gastrointestinal disturbances. Conjunctival
injection, flushing of the face, orthostatic
hypotension, petechiae on the palate and
axillae, and bleeding of the gums reflect
damage to the vascular bed. Hemorrhage
along the gingival margin is a character-
istic finding. Neurologic manifestations
are common. Laboratory findings early
in the course of disease nearly always in-
clude thrombocytopenia (platelet count
<100 000/mm3) and leukopenia (white
blood cell count <4000/mm3). By the second
week of the disease, 70% to 80% improve,
while the remaining 20% progress over the
next week or so with severe hemorrhagic
orneurologic manifestations.6
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Fig 1.
Management
General supportive therapy involves ade-
quate hydration, management of neurologic
conditions, blood transfusions, and other sup-
portive measures. Platelet transfusions are
probably not useful due to the complex na-
ture of hemorrhage. If initiated within 8 days,
transfusion of immune plasma for Argentine
HF has reduced mortality to less than 1%.8
There is limited human experience with rib-
avirin for the treatment of South American
HFs, but at least 1 study demonstrated a signifi-
cant drop in viremia for the Junin virus even in
the later stages of the disease.9 Ribavirin can
be used for treatment or prophylaxis of Lassa
fever. A 10-day IV course of ribavirin is effec-
tive at all stages of illness and oral dosing is
effective for postexposure prophylaxis.10 Al-
ternatively, ribavirin may be given IV for the
first 4 days followed by oral dosing to com-
plete the 10-day course.11 Starting ribavirin
before day 7 of illness was associated with a
higher survival rate.10 An effective live atten-
uated Junin virus vaccine is available in South
America to prevent Argentine HF in high-risk
populations.12
BUNYAVIRUS
Overview
The family Bunyaviridae contains at least
41 different tropical viruses, including those
that cause Crimean-Congo hemorrhagic fever
(CCHF), Rift Valley fever (RVF), HF with re-
nal syndrome, and hantavirus pulmonary syn-
drome. A tick-borne viral illness, CCHF causes
severe hemorrhagic manifestations and oc-
curs mainly in tropical Africa, temperate
Europe, and as far east as China.13 The dis-
ease is generally rural in distribution and
arises mainly among farm workers, many of
whom recount a history of tick bite or of
squeezing ticks with their fingers. Nosocomial
transmission of CCHF is common.14,15 The
case-to-infection ratio approaches 100%, with
a case-fatality rate of 15% to 30%.2
Rift Valley fever is primarily a mosquito-
borne (Aedes sp.) viral disease of sheep and
cattle but humans can acquire the infection
from aerosols generated from body fluids and
tissues of diseased animals or from bites of
infected mosquitoes. Person-to-person trans-
mission has not been reported. Based on
virus isolations, RVF occurs endemically dur-
ing the rainy season throughout most of sub-
Saharan Africa and more recently, in the Mid-
dle East.16,17 In 1977, an epidemic of RVF oc-
curred in Egypt, infecting over 200 000 and
killing 600.18 The case-to-infection ratio is
only about 1%, but the case-fatality rate is over
50% and nearly 100% for animals it infects.2
Clinical features
Crimean-Congo hemorrhagic fever is a se-
vere hemorrhagic fever with shock, dissem-
inated intravascular coagulation, and severe
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thrombocytopenia. In about 80% of cases,
CCHF is subclinical.13 After an incubation pe-
riod of 3 to 9 days, CCHF begins swiftly with
fever, headache, nausea, myalgia, vomiting,
abdominal pain, and conjunctival injection.19
In about half of the cases, hepatomegaly is
evident. Hemorrhagic manifestations do not
generally appear before the third or fourth
day of the illness. The onset of the hemor-
rhagic phase is marked by the appearance of
purpura on the skin and mucous membranes,
which lasts 3 to 6 days. Hemorrhages also de-
velop from the nose, gums, and buccal cav-
ity. In severe cases of CCHF, gastric, uterine,
intestinal, genitourinary, and pulmonary hem-
orrhages occur. In patients with profuse hem-
orrhage, tachycardia, shock, and death may
occur. If the patient survives the hemorrhagic
phase of the disease, by the ninth or tenth
day recovery begins and a 2- to 6-week period
of slow convalescence follows. Viremia is in-
tense and prolonged in CCHF, especially in fa-
tal cases. Blood from these patients should be
treated with extreme care.13
The incubation period of RVF is 3 to 7 days;
onset is sudden, with chills, myalgia, joint
pains, headache, and a biphasic fever that lasts
about 1 week. The patient often complains
of nausea, vomiting, and abdominal fullness
and pain. There is bradycardia, and there may
be slight tenderness over the liver, which may
be enlarged. Many patients become delirious,
and some have hallucinations. Three main
complications of RVF include encephalitis,
optic neuropathy, and hepatitis. About 10%
of patients experience optic neuritis, which
manifests as cotton-wool exudates on the
macula.20 Death usually follows massive gas-
trointestinal hemorrhage, oliguria, anuria, and
acute renal failure after 3 to 6 days.13
Management
An inactivated vaccine is available from the
US military for RVF and outside the United
States there is a vaccine for CCHF. For RVF,
interferon alpha has been used in doses of
5 × 105 units/kg for 5 days for primates.13
When ribavirin was used in Rhesus monkeys
with experimental RFV, a significant decline
in viremia was noted, but human trials have
not been done.21 The combination of rib-
avirin and interferon, RebetronTM, is not ap-
proved for RVF and published experience is
absent. For CCHF, immune serum appears use-
ful when given early in infection and at a dose
of 250 mL IV over 1 to 2 days.13 Ribavirin has
in-vitro activity against CCHF, but controlled
clinical trials are lacking. A published report
suggests that ribavirin given for postexposure
prophylaxis at an IV or PO dose of 2 g to load,
then 4 g/day in 4 divided doses for 4 days,
finally dropping to 2 g/day for 6 days for a
total of 10 days was beneficial at preventing
death.22
FILOVIRUS
Overview
The family Filoviridae is composed of 2
distinctive species, Marburg and Ebola, with
specific subtypes for each named after the
country where the virus was isolated in re-
lation to an outbreak (eg Ebola, Zaire). Ebola
was first described in 1976 in the Sudan and
Zaire. Twice Ebola has surfaced in the United
States as a result of infected primates, in Re-
ston Virginia in 1989 and in Texas in 1996,
but neither event resulted in spread beyond
lab workers, who remained asymptomatic, or
the infected primates.23 Both Ebola and Mar-
burg are rare infections, making it difficult to
study them in a controlled manner. The nat-
ural reservoir for Ebola is unknown, but it
appears to be effectively transmitted person-
to-person via contaminated blood and bodily
fluids or reused needles and from animal to
human.24 Filoviruses are exceedingly virulent
in humans, with case-fatalities rates up to
100%.25
Clinical features
Both Ebola and Marburg virus infections
have a similar course of illness. Following a 5-
to 10-day incubation period there is an abrupt
onset of fever usually associated with myal-
gia and severe frontal headache. Disease pro-
gression is characterized by nausea, pharyn-
gitis, photophobia, severe vomiting of blood,
and diarrhea. Hemorrhagic symptoms include
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epistaxis, bleeding gums, hematemesis, and
bleeding from sites of needle insertion.26 Af-
ter 5 to 7 days, a nonpruritic maculopapu-
lar rash develops. Neurologic symptoms in-
clude somnolence, delirium, or coma. A poor
prognosis is marked by hemorrhagic signs, as
well as oliguria or anuria, chest pain, shock,
tachypnea, and neurologic symptoms. If fatal,
death occurs 6 to 9 days after onset of the
clinical disease and results from severe blood
loss and shock. Clinical laboratory findings
show an early lymphopenia and a thrombocy-
topenia. Liver function enzyme levels (aspar-
tate aminotransferose and alanine aminotrans-
ferase) are elevated. Viral isolation is not prac-
tical since it requires a biosafety level 4 labora-
tory; thus samples must be sent to the Centers
for Disease Control and Prevention for confir-
mation.
Management
Ribavirin does not have good in-vitro ac-
tivity against Ebola and Marburg and has not
been shown to be effective in animals.27 Ther-
apy centers around supportive care, primarily
volume replacement, correcting electrolyte
imbalances, pressure support, and transfu-
sions and heparin for disseminated intravascu-
lar coagulation. Convalescent immune serum
and human interferon probably have limited
utility as clinical experience is lacking and in-
vitro data suggests IV fluids have not reversed
hypotension and may have contributed to pul-
monary edema.
FLAVIVIRIDAE
Overview
Flaviviridae are a diverse group of RNA
viruses containing Hepacivirus (Hepatitis C)
and the genus flavivirus, which causes yel-
low fever (YF), dengue hemorrhagic fever
(DHF), Japanese encephalitis, and tick-borne
ecephalitis. Yellow fever is a mosquito-borne
(Aedes aegypti) infection endemic to nonur-
ban areas of tropical South America and sub-
Saharan Africa. Up to 50% of hemorrhagic–
fever-related mortality worldwide can be at-
tributed to YF.28 The World Health Organi-
zation estimates that there are over 200 000
cases annually of YF and over 6400 deaths,
with more than 90% acquired in Africa.29
The case-fatality rate varies from 20% to
50%.2 A highly effective live attenuated vac-
cine is available in the United States and
abroad for the prevention of YF. Since 1996, 3
deaths have occurred in unvaccinated people,
most recently in a returned traveler from the
Amazon.30 Dengue fever (DF) virus is fast on
its way to becoming the world’s major emerg-
ing infection. Transmitted by mosquito bites
(A. aegypti and A. albopictus) during the day
in about 101 countries, DF infects about 50
to 100 million people worldwide and DHF af-
fects about 250 000 to 500 000.31 More than
half of the world’s population lives in a DF-
infected area, including the United States. In
the United States, Texas and Hawaii have re-
cently experienced DF outbreaks, adding to
the approximate 20 cases per year of labo-
ratory confirmed imported DF cases.32 Case-
fatality rates for DHF vary from <1% to 5% up
to 12% to 44% for dengue shock syndrome, a
variant of DF.33
Clinical features
Yellow fever
After a 3- to 6-day incubation period, there
is an abrupt onset of flu-like symptoms in-
cluding fever, chills, malaise, headache, myal-
gia, nausea, and dizziness. Classic YF displays
3 clinical periods: infection (sudden on-
set of flu-like symptoms with bradycardia),
remission (lasting about 24 hours before
the return of symptoms), and intoxication
(jaundice, albuminuria, oliguria, cardiovascu-
lar instability, hemorrhagic manifestations).28
When death occurs, it usually happens around
day 7 to 10 as a result of ongoing liver failure
and metabolic acidosis.
Dengue hemorrhagic fever
Dengue fever manifests with a sudden on-
set of fever and flu-like symptoms that spon-
taneously resolve after 3 to 7 days. Circulat-
ing antibodies from a previously acquired DF
infection appear to be a strong indicator of
progression to DHF.31 Classically, DHF is a
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disease of children, characterized by a sud-
den onset of fever with other non-specific
symptoms. Unfortunately, there is no pathog-
nomonic sign or symptom to help clinicians
differentiate DHF from other childhood ill-
nesses and many infections are asymptomatic.
The World Health Organization provides a
classification of DF from grade 1 to 4 based
on severity of illness. As the illness progresses
through the stages of infection, the patient
begins to experience hemorrhagic symptoms
(skin, gums, and gastrointestinal tract) with
thrombocytopenia, circulatory failure, shock,
and finally death.
Management
Prevention through vaccination and
mosquito bite avoidance are the mainstays
of minimizing the risk of YF. A single dose
of the 17D live attenuated vaccine after 10
days provides nearly complete protection for
at least 10 years.34 A combination of DEET
insect repellant (at least 30%) applied to
the skin and permethrin insecticide applied
to the clothing, both worn during the day,
is an important means of preventing bites
from mosquitoes carrying DF or YF. Although
ribavirin may be effective in the treatment
of arenaviruses and bunyaviruses, it does not
appear to be effective in the treatment of
flavivirus infections, including DHF and YF.27
Experience is limited with severe YF infec-
tion, but symptomatic management of fluids,
electrolytes, and circulatory support appears
warranted. Dengue hemorrhagic fever often
responds to early fluid replacement, often
with reversal of disseminated intravascular
coagulation.35 Early intervention for shock re-
quires knowing how much time has elapsed
since the onset of infection (DHF usually
occurs around day 3 to 7) and monitoring
for a rapidly decreasing platelet count with
a rising hematocrit.31 There is no vaccine or
drug available for the prevention or treatment
of DF.
RECOMMENDATIONS
Viral hemorrhagic fevers are primarily im-
ported diseases from the tropics. Emergency
Department personnel should be aware of the
clinical presentation, management, and infec-
tion control procedures for VHF. When a VHF
is highly suspected, it is important to institute
strict infection control procedures (ie per-
sonal protective measures, contact, and respi-
ratory isolation) for arenaviruses, such as that
causing Lassa fever, bunyaviruses, such as that
causing Crimean-Congo hemorrhagic fever,
and filoviruses, such as Marburg and Ebola,
due to their potential for person-to-person
transmission. Local and state health depart-
ment and the Centers for Disease Control and
Prevention should be notified immediately
when a case of VHF is suspected. In the event
of a VHF related to bioterrorism, the Work-
ing Group on Civilian Biodefense has issued
guidelines for isolation precautions, personal
protective equipment, laboratory testing,
postmortem practices, and environmental
decontamination.4 In the words of one of the
world’s foremost virus hunters, “I don’t pre-
tend to be able to predict what the next great
disease will be . . . [however] I believe it is pos-
sible to identify some of the most dangerous
pieces of the puzzle beforehand.”1
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